tiprankstipranks
Advertisement
Advertisement
Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk
PremiumCompany AnnouncementsAmarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk
2M ago
Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds
Premium
Company Announcements
Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds
2M ago
Amarin highlights recent data published on REDUCE-IT study
Premium
The Fly
Amarin highlights recent data published on REDUCE-IT study
2M ago
Amarin comments on recent innovations for patients with elevated triglycerides
PremiumThe FlyAmarin comments on recent innovations for patients with elevated triglycerides
4M ago
Amarin expects Q4 net revenue $48M-$43M
Premium
The Fly
Amarin expects Q4 net revenue $48M-$43M
4M ago
Amarin believes it’s in ‘best position’ to capitalize on opportunities in FY26
Premium
The Fly
Amarin believes it’s in ‘best position’ to capitalize on opportunities in FY26
4M ago
Amarin reports Q3 EPS (2c) vs (6c) last year
PremiumThe FlyAmarin reports Q3 EPS (2c) vs (6c) last year
6M ago
Amarin issues statement related to recent action by FDA for fenofibrate drugs
Premium
The Fly
Amarin issues statement related to recent action by FDA for fenofibrate drugs
6M ago
Is AMRN a Buy, Before Earnings?
Premium
Pre-Earnings
Is AMRN a Buy, Before Earnings?
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100